Sareum Holdings (LSE:SAR) has reached an important development milestone after completing dosing in the Phase 2-enabling toxicology programme for its lead drug candidate, SDC-1801. The selective oral TYK2/JAK1 inhibitor is being developed to treat autoimmune diseases, with psoriasis identified as the initial target indication. The company is now evaluating the toxicology results while continuing chemistry, manufacturing, controls and formulation activities. Sareum expects to complete the full Phase 2-enabling regulatory package during the fourth quarter of 2026 using its existing cash resources, paving the way for planned Phase 2 clinical studies and supporting the advancement of its broader pipeline in autoimmune and oncology therapies.
Despite this operational progress, Sareum remains in the clinical development stage and has yet to generate revenue. The business continues to report operating losses and cash outflows as it funds research and development, meaning future financing may be required. While technical indicators point to a positive share price trend, momentum appears elevated, suggesting the stock may be approaching overbought territory. Valuation also remains limited by negative earnings and the absence of dividend income.
More about Sareum Holdings
Sareum Holdings plc is a Cambridge-based clinical-stage biotechnology company listed on AIM under the ticker SAR. The business specialises in developing next-generation small-molecule kinase inhibitors that target the JAK signalling pathway.
Its lead programme, SDC-1801, is focused on autoimmune diseases including psoriasis, while its wider pipeline includes SDC-1802 and the licensed oncology asset SRA737. Through these programmes, Sareum aims to develop new treatments for autoimmune disorders, cancer and neuroinflammatory diseases.
Leave a Reply